What are the responsibilities and job description for the Postdoctoral Fellowship in in Molecular Imaging and Theranostics position at The Johns Hopkins University School of Medicine?
An NIH-funded postdoctoral fellowship is available in the Nimmagadda Laboratory in the Russell H. Morgan Department of Radiology and Radiological Science at the Johns Hopkins University School of Medicine. Our multidisciplinary research program develops molecular imaging probes and theranostic agents for cancer — including targeted alpha therapy and quantitative imaging of drug–target engagement — with an emphasis on translating promising agents from chemical design and synthesis through preclinical and clinical evaluation.
We seek a highly motivated candidate with extensive experience in organic, medicinal, or peptide chemistry and a strong record of chemical synthesis. Prior radiochemistry experience is not required, but the candidate should be enthusiastic about learning radiolabeling techniques and working with radioactive materials.
Qualifications• PhD in chemistry, medicinal chemistry, chemical biology, or a related field
• Within 1-2 years of receiving PhD.
• Extensive hands-on experience in chemical synthesis, purification, and analytical characterization (HPLC, LC-MS, NMR)
• Strong record of productivity and excellent written and oral communication skills
EnvironmentThe fellow will join a highly collaborative environment with access to state-of-the-art radiochemistry, small-animal PET/CT, and translational imaging resources, with strong ties to clinical programs at Johns Hopkins.
Representative Recent Publications1. Mishra A, Sharma AK, Gupta K, Banka DS, Johnson BA, Hoffman-Censits J, Huang P, McConkey DJ, Nimmagadda S. Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. Science Advances. 2026 Jan 9;12(2):eady1111.
2. Sharma AK, et al., Nimmagadda S. EphA2-targeted alpha-particle theranostics for enhancing PDAC treatment. Theranostics. 2025;15(10).
3. Sharma AK, Mishra A, Gupta K, Nimmagadda S. SuFEx and macrocyclic chelation define orthogonal reactivity domains enabling isotopically versatile radiopharmaceuticals from a single peptide precursor. bioRxiv [Preprint]. 2026 Jun 22. doi:10.64898/2026.05.27.728245.
Interested candidates should send a cover letter describing their research experience and interests, a curriculum vitae, and contact information for three references to Dr. Sridhar Nimmagadda at snimmag1@jhmi.edu.